Developer docs
API playgroundTry for free, no card

Search company profiles

Autoimmune Neurology Alliance

Full company profile

uuid00st93o

Namestring
Autoimmune Neurology Alliance
Legal namestring
Autoimmune Neurology Alliance
Websiteurl
ainalliance.org
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Autoimmune Neurology Alliance (AiNA) is a 501(c)(3) public charity (IRS EIN 39-5058002; Massachusetts AGO Charity Number 086739) dedicated to advancing research in rare autoimmune neurological disorders. Its sole core product is the AXIS Autoimmune Neurology Registry, a 10-year longitudinal, patient-centered research platform launched in 2024 starting with myasthenia gravis (MG), with planned expansion to chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The registry captures monthly digital questionnaire data on symptom variability, treatment use, and quality of life using validated instruments (MG-ADL and MG-QOL-15r), is governed by both a Scientific Advisory Committee and a Patient Governance Committee, and is designed for linkage with clinician-reported and administrative claims data to support comprehensive real-world evidence generation.

The platform was developed in partnership with Alira Health, which provides research and technology expertise. Patient enrollment is self-serve through a dedicated portal (axispatientregistry.com), with diagnosis-confirmed enrollment and optional patient-co-developed modules. AiNA's go-to-market is community-led, relying on its organizational website (ainalliance.org), direct outreach, and partnerships with patient advocacy groups, academic researchers, neurologists, life science companies, and non-profits.

As a non-profit, AiNA generates revenue exclusively through charitable donations, offering preset amounts of $10, $20, $30, and $40 with custom options across one-time, weekly, monthly, quarterly, and annual frequencies, and the ability for donors to designate contributions to a specific condition. No revenue figures, headcount, or funding rounds are disclosed, and no management team or external investors are identified in the available data.

Short descriptiontext

Autoimmune Neurology Alliance (AiNA) is a 501(c)(3) non-profit operating the AXIS Autoimmune Neurology Registry, a 10-year longitudinal research platform capturing real-world patient experiences across myasthenia gravis and related autoimmune neurological conditions for use by patients, researchers, neurologists, and life science companies.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
Markets served

Serves global market

Keyword5 values
patient registry platform, autoimmune neurology research, real-world evidence generation, longitudinal health data, patient-reported outcomes
Industry2 codes
1Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
CodeHLACAOAMPrimaryYes
2eCOA/ePRO/eDiary & Patient-Facing Data Collection
CodeHLACAOABPrimaryNo
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Patient Registry & Real-World Evidence Research
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Charitable Contributions
TypeGrants Donations
Description

As a 501(c)(3) public charity, AiNA relies on tax-deductible donations from individuals, organizations, and potentially institutional funders. The organization accepts one-time, weekly, monthly, quarterly, and annual donations with preset amounts ($10, $20, $30, $40) and custom amounts. Donors can optionally cover transaction fees.

ainalliance.org
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Preset Donation Amounts
ModelOtherBilling cadenceMonthly
Notes

$10, $20, $30, $40 preset donation options available with custom amount option. Donors can select one-time, weekly, monthly, quarterly, or annual donation frequencies. Optional 3% fee coverage to support operational costs.

ainalliance.org
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Autoimmune Neurology Alliance (AiNA) operates the AXIS Autoimmune Neurology Registry, a 10-year longitudinal, patient-centered research platform that captures real-world experiences of people living with autoimmune neurological conditions (starting with myasthenia gravis, with planned expansion to CIDP, GBS, NMOSD, and MOGAD). Participants complete monthly digital questionnaires using validated instruments (MG-ADL and MG-QOL-15r), with the platform developed in partnership with Alira Health and governed by a Scientific Advisory Committee and a Patient Governance Committee.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10-year longitudinal data capture with monthly digital questionnaires
+2 more records
Product overview1 text field

Autoimmune Neurology Alliance is a 501(c)(3) non-profit organization operating as a single-product entity centered on the AXIS Autoimmune Neurology Registry. AXIS is a longitudinal research registry developed in partnership with Alira Health that captures real-world patient experiences across autoimmune neurological conditions (starting with myasthenia gravis), using monthly digital questionnaires with validated clinical instruments to generate evidence for research, care delivery, and drug development. The organization also accepts donations designated to specific autoimmune neurological conditions (MG, CIDP, GBS, NMOSD, MOGAD).

Product and service1 record
1AXIS Autoimmune Neurology Registry
CategoryPatient Registry / Real-World Evidence Platform
Description

A 10-year longitudinal, patient-centered research registry that captures real-world experiences of people living with autoimmune neurological conditions, starting with myasthenia gravis and expanding to other conditions (CIDP, GBS, NMOSD, MOGAD). It collects monthly digital questionnaire data on symptom variability, treatment use, and quality of life using validated instruments (MG-ADL, MG-QOL-15r), with governance by a Scientific Advisory Committee and a Patient Governance Committee. Designed for researchers, clinicians, life science companies, patient advocacy groups, and patients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Alira Health is a strategic partner in the development and operation of the AXIS Autoimmune Neurology Registry. The registry is described as 'Developed by the Autoimmune Neurology Alliance in partnership with Alira Health.' Alira Health brings research and technology expertise to this 10-year longitudinal research initiative designed to capture real-world experiences of people living with autoimmune neurology conditions.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Antidote (formerly TrialReach)
TypeEmerging player
Description

A digital patient engagement and clinical trial matching platform that connects patients with rare diseases to research opportunities. Comparable as enabling infrastructure for patient recruitment into registries and trials, including autoimmune and neurological conditions served by AiNA.

TypeEmerging player
Description

A healthcare and life sciences advisory and technology firm that is AiNA's strategic partner on the AXIS Registry. It is comparable as a builder of real-world evidence platforms and clinical research infrastructure for patient foundations and life-science clients.

3The Guthy-Jackson Charitable Foundation
TypeDirect peer
Description

A leading research-driven non-profit focused exclusively on NMOSD, one of AiNA's target conditions. Like AiNA, it funds research and builds scientific infrastructure around a rare autoimmune neurological disorder, making it a directly comparable disease-focused research foundation.

TypeBroad incumbent
Description

A global provider of advanced analytics, technology solutions, and real-world evidence services to the life-sciences industry. Comparable to AiNA as a supplier of real-world evidence and clinical research informatics, though at vastly greater scale and across all therapeutic areas.

TypeBroad incumbent
Description

A global health research network providing real-world data and observational research capabilities to life-science companies and academic researchers. It is comparable to AXIS as a real-world evidence and observational research platform, though broader in scope and not disease-specific.

TypeDirect peer
Description

A patient advocacy and research funding non-profit for sarcoidosis. It is comparable as a rare-disease non-profit combining community engagement, research funding, and patient-centered evidence generation, analogous to AiNA's autoimmune neurology mission.

TypeDirect peer
Description

A national patient advocacy and research organization for myasthenia gravis, directly comparable to AiNA's lead disease focus. MGFA also funds research and supports patient engagement, and represents both a potential partner and overlapping registry stakeholder in the same condition.

TypeDirect peer
Description

A non-profit that accelerates research into Castleman disease by coordinating patients, clinicians, and researchers and building research infrastructure. Closely mirrors AiNA's model of a small, research-focused non-profit building patient-centered evidence infrastructure for a rare disease.

TypeDirect peer
Description

A patient advocacy and research foundation covering GBS and CIDP, two of AiNA's five target conditions. It is directly comparable as a disease-focused non-profit combining advocacy, patient engagement, and research support in autoimmune neurology.

TypeDirect peer
Description

A patient-driven non-profit supporting research and community for NMOSD and MOGAD, both within AiNA's scope. It mirrors AiNA's model of combining patient advocacy with research infrastructure in a rare autoimmune neurology niche.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Autoimmune Neurology Alliance

Patient Registry & Real-World Evidence Researchainalliance.org

Autoimmune Neurology Alliance (AiNA) is a 501(c)(3) non-profit operating the AXIS Autoimmune Neurology Registry, a 10-year longitudinal research platform capturing real-world patient experiences across myasthenia gravis and related autoimmune neurological conditions for use by patients, researchers, neurologists, and life science companies.

What Autoimmune Neurology Alliance does

Autoimmune Neurology Alliance (AiNA) is a 501(c)(3) public charity (IRS EIN 39-5058002; Massachusetts AGO Charity Number 086739) dedicated to advancing research in rare autoimmune neurological disorders. Its sole core product is the AXIS Autoimmune Neurology Registry, a 10-year longitudinal, patient-centered research platform launched in 2024 starting with myasthenia gravis (MG), with planned expansion to chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome (GBS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The registry captures monthly digital questionnaire data on symptom variability, treatment use, and quality of life using validated instruments (MG-ADL and MG-QOL-15r), is governed by both a Scientific Advisory Committee and a Patient Governance Committee, and is designed for linkage with clinician-reported and administrative claims data to support comprehensive real-world evidence generation.

The platform was developed in partnership with Alira Health, which provides research and technology expertise. Patient enrollment is self-serve through a dedicated portal (axispatientregistry.com), with diagnosis-confirmed enrollment and optional patient-co-developed modules. AiNA's go-to-market is community-led, relying on its organizational website (ainalliance.org), direct outreach, and partnerships with patient advocacy groups, academic researchers, neurologists, life science companies, and non-profits.

As a non-profit, AiNA generates revenue exclusively through charitable donations, offering preset amounts of $10, $20, $30, and $40 with custom options across one-time, weekly, monthly, quarterly, and annual frequencies, and the ability for donors to designate contributions to a specific condition. No revenue figures, headcount, or funding rounds are disclosed, and no management team or external investors are identified in the available data.

Autoimmune Neurology Alliance firmographics

Firmographics
Name
Autoimmune Neurology Alliance
Legal name
Autoimmune Neurology Alliance
Website
https://ainalliance.org
Company type
Private
Operating status
Operating
Short description
Autoimmune Neurology Alliance (AiNA) is a 501(c)(3) non-profit operating the AXIS Autoimmune Neurology Registry, a 10-year longitudinal research platform capturing real-world patient experiences across myasthenia gravis and related autoimmune neurological conditions for use by patients, researchers, neurologists, and life science companies.
Ownership category
akta.pro rank

Autoimmune Neurology Alliance industry classification

Industry
Product category
Patient Registry & Real-World Evidence Research
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro primary industry
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)
akta.pro secondary industry
eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)

Keywords

  • Patient registry platform
  • Autoimmune neurology research
  • Real-world evidence generation
  • Longitudinal health data
  • Patient-reported outcomes

Autoimmune Neurology Alliance business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Donations and Charitable Contributions: As a 501(c)(3) public charity, AiNA relies on tax-deductible donations from individuals, organizations, and potentially institutional funders. The organization accepts one-time, weekly, monthly, quarterly, and annual donations with preset amounts ($10, $20, $30, $40) and custom amounts. Donors can optionally cover transaction fees.

Pricing tiers

ModelBillingPrice
OtherMonthlyPreset Donation Amounts

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Autoimmune Neurology Alliance product offering

Product offering

Core offering

Autoimmune Neurology Alliance (AiNA) operates the AXIS Autoimmune Neurology Registry, a 10-year longitudinal, patient-centered research platform that captures real-world experiences of people living with autoimmune neurological conditions (starting with myasthenia gravis, with planned expansion to CIDP, GBS, NMOSD, and MOGAD). Participants complete monthly digital questionnaires using validated instruments (MG-ADL and MG-QOL-15r), with the platform developed in partnership with Alira Health and governed by a Scientific Advisory Committee and a Patient Governance Committee.

Product overview

Autoimmune Neurology Alliance is a 501(c)(3) non-profit organization operating as a single-product entity centered on the AXIS Autoimmune Neurology Registry. AXIS is a longitudinal research registry developed in partnership with Alira Health that captures real-world patient experiences across autoimmune neurological conditions (starting with myasthenia gravis), using monthly digital questionnaires with validated clinical instruments to generate evidence for research, care delivery, and drug development. The organization also accepts donations designated to specific autoimmune neurological conditions (MG, CIDP, GBS, NMOSD, MOGAD).

Differentiator

Problem solved

Functional benefit

Products and services

  • AXIS Autoimmune Neurology Registry A 10-year longitudinal, patient-centered research registry that captures real-world experiences of people living with autoimmune neurological conditions, starting with myasthenia gravis and expanding to other conditions (CIDP, GBS, NMOSD, MOGAD). It collects monthly digital questionnaire data on symptom variability, treatment use, and quality of life using validated instruments (MG-ADL, MG-QOL-15r), with governance by a Scientific Advisory Committee and a Patient Governance Committee. Designed for researchers, clinicians, life science companies, patient advocacy groups, and patients.

Quantifiable outcome

  • 10-year longitudinal data capture with monthly digital questionnaires
  • +2 more outcomes

Companies that use Autoimmune Neurology Alliance

Customer profile

Segments4 records

Ideal customer profiles4 records

Autoimmune Neurology Alliance technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Autoimmune Neurology Alliance partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Alira HealthcoreStrategic or Co-development PartnerAlira Health is a strategic partner in the development and operation of the AXIS Autoimmune Neurology Registry. The registry is described as 'Developed by the Autoimmune Neurology Alliance in partnership with Alira Health.' Alira Health brings research and technology expertise to this 10-year longitudinal research initiative designed to capture real-world experiences of people living with autoimmune neurology conditions.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Autoimmune Neurology Alliance competitors and assessment

Company assessment

Emerging players

  • Antidote (formerly TrialReach): A digital patient engagement and clinical trial matching platform that connects patients with rare diseases to research opportunities. Comparable as enabling infrastructure for patient recruitment into registries and trials, including autoimmune and neurological conditions served by AiNA.
  • Alira Health: A healthcare and life sciences advisory and technology firm that is AiNA's strategic partner on the AXIS Registry. It is comparable as a builder of real-world evidence platforms and clinical research infrastructure for patient foundations and life-science clients.

Direct peers

  • The Guthy-Jackson Charitable Foundation: A leading research-driven non-profit focused exclusively on NMOSD, one of AiNA's target conditions. Like AiNA, it funds research and builds scientific infrastructure around a rare autoimmune neurological disorder, making it a directly comparable disease-focused research foundation.
  • Foundation for Sarcoidosis Research: A patient advocacy and research funding non-profit for sarcoidosis. It is comparable as a rare-disease non-profit combining community engagement, research funding, and patient-centered evidence generation, analogous to AiNA's autoimmune neurology mission.
  • Myasthenia Gravis Foundation of America: A national patient advocacy and research organization for myasthenia gravis, directly comparable to AiNA's lead disease focus. MGFA also funds research and supports patient engagement, and represents both a potential partner and overlapping registry stakeholder in the same condition.
  • Castleman Disease Collaborative Network: A non-profit that accelerates research into Castleman disease by coordinating patients, clinicians, and researchers and building research infrastructure. Closely mirrors AiNA's model of a small, research-focused non-profit building patient-centered evidence infrastructure for a rare disease.
  • GBS/CIDP Foundation International: A patient advocacy and research foundation covering GBS and CIDP, two of AiNA's five target conditions. It is directly comparable as a disease-focused non-profit combining advocacy, patient engagement, and research support in autoimmune neurology.
  • The Sumaira Foundation for NMO: A patient-driven non-profit supporting research and community for NMOSD and MOGAD, both within AiNA's scope. It mirrors AiNA's model of combining patient advocacy with research infrastructure in a rare autoimmune neurology niche.

Broad incumbents

  • IQVIA: A global provider of advanced analytics, technology solutions, and real-world evidence services to the life-sciences industry. Comparable to AiNA as a supplier of real-world evidence and clinical research informatics, though at vastly greater scale and across all therapeutic areas.
  • TriNetX: A global health research network providing real-world data and observational research capabilities to life-science companies and academic researchers. It is comparable to AXIS as a real-world evidence and observational research platform, though broader in scope and not disease-specific.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Autoimmune Neurology Alliance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Autoimmune Neurology Alliance leadership team

Management profile

Number of profiles

Autoimmune Neurology Alliance funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Autoimmune Neurology Alliance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autoimmune Neurology Alliance

What does Autoimmune Neurology Alliance do?

Autoimmune Neurology Alliance (AiNA) operates the AXIS Autoimmune Neurology Registry, a 10-year longitudinal, patient-centered research platform that captures real-world experiences of people living with autoimmune neurological conditions (starting with myasthenia gravis, with planned expansion to CIDP, GBS, NMOSD, and MOGAD). Participants complete monthly digital questionnaires using validated instruments (MG-ADL and MG-QOL-15r), with the platform developed in partnership with Alira Health and governed by a Scientific Advisory Committee and a Patient Governance Committee.

Is Autoimmune Neurology Alliance a public or private company?

Autoimmune Neurology Alliance is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Autoimmune Neurology Alliance founded?

Autoimmune Neurology Alliance was founded in -1.

How does Autoimmune Neurology Alliance make money?

One revenue line is on record: donations and Charitable Contributions.

Who are Autoimmune Neurology Alliance's main competitors?

Emerging players on record are Antidote (formerly TrialReach) and Alira Health. Direct peers are The Guthy-Jackson Charitable Foundation, Foundation for Sarcoidosis Research, Myasthenia Gravis Foundation of America, Castleman Disease Collaborative Network, GBS/CIDP Foundation International and The Sumaira Foundation for NMO. Broad incumbents are IQVIA and TriNetX.

Does Autoimmune Neurology Alliance have an API?

No public API is recorded for Autoimmune Neurology Alliance.

What industry is Autoimmune Neurology Alliance in?

Autoimmune Neurology Alliance's product category is Patient Registry & Real-World Evidence Research. Its primary akta.pro industry code is HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms, with a secondary code of HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its NAICS code is 54171 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals